These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

133 related items for PubMed ID: 18555565

  • 1. Indirect foot-and-mouth disease vaccine potency testing based on a serological alternative.
    Goris N, Willems T, Diev VI, Merkelbach-Peters P, Vanbinst T, Van der Stede Y, Kraft HP, Zakharov VM, Borisov VV, Nauwynck HJ, Haas B, De Clercq K.
    Vaccine; 2008 Jul 23; 26(31):3870-9. PubMed ID: 18555565
    [Abstract] [Full Text] [Related]

  • 2. Characteristics of serology-based vaccine potency models for foot-and-mouth disease virus.
    Willems T, Lefebvre DJ, Goris N, Diev VI, Kremenchugskaya SR, Paul G, Haas B, De Clercq K.
    Vaccine; 2012 Aug 31; 30(40):5849-55. PubMed ID: 22824343
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Updating of the correlation between lpELISA titers and protection from virus challenge for the assessment of the potency of polyvalent aphtovirus vaccines in Argentina.
    Maradei E, La Torre J, Robiolo B, Esteves J, Seki C, Pedemonte A, Iglesias M, D'Aloia R, Mattion N.
    Vaccine; 2008 Dec 02; 26(51):6577-86. PubMed ID: 18835312
    [Abstract] [Full Text] [Related]

  • 5. Confidence in indirect assessment of foot-and-mouth disease vaccine potency and vaccine matching carried out by liquid phase ELISA and virus neutralization tests.
    Robiolo B, La Torre J, Maradei E, Beascoechea CP, Perez A, Seki C, Smitsaart E, Fondevila N, Palma E, Goris N, De Clercq K, Mattion N.
    Vaccine; 2010 Aug 31; 28(38):6235-41. PubMed ID: 20643090
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Human adenovirus-vectored foot-and-mouth disease vaccines: establishment of a vaccine product profile through in vitro testing.
    Brake DA, McIlhaney M, Miller T, Christianson K, Keene A, Lohnas G, Purcell C, Neilan J, Schutta C, Barrera J, Burrage T, Brough DE, Butman BT.
    Dev Biol (Basel); 2012 Aug 31; 134():123-33. PubMed ID: 22888605
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Analysis of the immune response to FMDV structural and non-structural proteins in cattle in Argentina by the combined use of liquid phase and 3ABC-ELISA tests.
    Robiolo B, Seki C, Fondevilla N, Grigera P, Scodeller E, Periolo O, La Torre J, Mattion N.
    Vaccine; 2006 Feb 13; 24(7):997-1008. PubMed ID: 16171905
    [Abstract] [Full Text] [Related]

  • 15. Quantitative single serum-dilution liquid phase competitive blocking ELISA for the assessment of herd immunity and expected protection against foot-and-mouth disease virus in vaccinated cattle.
    Robiolo B, La Torre J, Duffy S, Leon E, Seki C, Torres A, Mattion N.
    J Virol Methods; 2010 Jun 13; 166(1-2):21-7. PubMed ID: 20170683
    [Abstract] [Full Text] [Related]

  • 16. Foot-and-mouth disease vaccine potency testing: the influence of serotype, type of adjuvant, valency, fractionation method, and virus culture on the dose-response curve in cattle.
    Jamal SM, Bouma A, van den Broek J, Stegeman A, Chénard G, Dekker A.
    Vaccine; 2008 Nov 25; 26(50):6317-21. PubMed ID: 18822336
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.